MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s43018-024-00814-0

Медицинская библиотека · Nature cancer · 2024

BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models.

Rauh Ulrike, Wei Guo, Serrano-Wu Michael, Kosmidis Georgios, Kaulfuss Stefan, Siegel Franziska, Thede Kai, McFarland James, Lemke Christopher T, Werbeck Nicolas, Nowak-Reppel Katrin, Pilari Sabine, Menz Stephan, Ocker Matthias, Zhang Weiqun, Davis Kyle, Poncet-Montange Guillaume, Roth Jennifer, Daniels Douglas, Kaushik Virendar K, Hubbard Brian, Ziegelbauer Karl, Golub Todd R

СтатьяПоддержка NIH: внешняя программаПеревод пока не подготовлен

Аннотация

The MCL1 gene is frequently amplified in cancer and codes for the antiapoptotic protein myeloid cell leukemia 1 (MCL1), which confers resistance to the current standard of care. Therefore, MCL1 is an attractive anticancer target. Here we describe BRD-810 as a potent and selective MCL1 inhibitor and its key design principle of rapid systemic clearance to potentially minimize area under the curve-driven toxicities associated with MCL1 inhibition. BRD-810 induced rapid cell killing within 4 h in vitro but, in the same 4-h window, had no impact on cell viability or troponin I release in human induced pluripotent stem cell-derived cardiomyocytes, even at suprapharmacologic concentrations. In vivo BRD-810 induced efficacy in xenograft hematological and solid tumor models despite the short residence time of BRD-810 in plasma. In totality, our data support the hypothesis that short-term inhibition of MCL1 with BRD-810 can induce apoptosis in tumor cells while maintaining an acceptable safety profile. We, therefore, intend to advance BRD-810 to clinical trials.

Для цитирования: Rauh Ulrike, Wei Guo, Serrano-Wu Michael, Kosmidis Georgios, Kaulfuss Stefan, Siegel Franziska, Thede Kai, McFarland James, Lemke Christopher T, Werbeck Nicolas, Nowak-Reppel Katrin, Pilari Sabine, Menz Stephan, Ocker Matthias, Zhang Weiqun, Davis Kyle, Poncet-Montange Guillaume, Roth Jennifer, Daniels Douglas, Kaushik Virendar K, Hubbard Brian, Ziegelbauer Karl, Golub Todd R. BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models.. Nature cancer. 2024. DOI: 10.1038/s43018-024-00814-0.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.